Enzo BioChem’s sale of its clinical lab business to Labcorp is the culmination of a monthslong strategic review. Meanwhile, diagnostics and lab testing giant Labcorp is in the middle of its own corporate shakeup as it readies its clinical trials business for a spinoff as a standalone, publicly traded company.
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Crescendo Health recently launched with a $3.4 million initial investment. The startup provides clinical researchers with software tools that make it easier to gather study participants' longitudinal health data.
The goal of implementing artificial intelligence and machine learning in clinical research is not to replace humans with digital tools but to increase their productivity.
The Series B funding round was led by DFJ Growth. Osmind helps the medical community administer treatments, and track and study the effectiveness of those treatments for 14 million U.S. patients living with moderate and serious mental illness, according to the company.
Staffing shortages can slow down trial timelines and negatively affect patients, who have less time with the physicians and nurses providing their care. But a few flexible, integrated systems that work for both clinical research sites and sponsors could help alleviate these issues and speed up research.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Underrepresented groups traditionally were thought to have limited access to technology. But internet access is on the rise and researchers can take steps to increase participant diversity and be more inclusive.
IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company's Q2 Solutions unit. The deal follows IQVIA's April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
The company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Boston Children's Hospital has joined TriNetX's global health research network, which is geared toward healthcare organizations, contract research organizations and biopharma companies. Through membership, Boston Children's can collaborate with other institutions, improve clinical trial design and refine recruitment techniques.
NXT Ventures and Rally Ventures led the financing round with participation from CRIO's officers, angel investors, and customers.